Research Analysts Set Expectations for ITRM FY2026 Earnings

Iterum Therapeutics plc (NASDAQ:ITRM) – Research analysts at HC Wainwright boosted their FY2026 earnings per share estimates for Iterum Therapeutics in a research report issued on Thursday, June 12th. HC Wainwright analyst M. Keller now anticipates that the company will earn $0.10 per share for the year, up from their prior estimate of $0.06. HC Wainwright currently has a “Buy” rating and a $9.00 target price on the stock. The consensus estimate for Iterum Therapeutics’ current full-year earnings is ($0.86) per share. HC Wainwright also issued estimates for Iterum Therapeutics’ FY2027 earnings at $0.75 EPS.

Iterum Therapeutics Trading Down 0.9%

Iterum Therapeutics stock opened at $0.99 on Friday. Iterum Therapeutics has a twelve month low of $0.81 and a twelve month high of $3.02. The stock’s fifty day simple moving average is $1.04 and its 200-day simple moving average is $1.42. The firm has a market capitalization of $39.64 million, a P/E ratio of -0.76 and a beta of 2.78.

Iterum Therapeutics (NASDAQ:ITRM) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.14) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.14).

Hedge Funds Weigh In On Iterum Therapeutics

Several large investors have recently bought and sold shares of the business. Renaissance Technologies LLC purchased a new position in Iterum Therapeutics in the fourth quarter valued at $777,000. OneDigital Investment Advisors LLC purchased a new position in Iterum Therapeutics in the first quarter valued at $124,000. Two Sigma Investments LP purchased a new position in Iterum Therapeutics in the fourth quarter valued at $45,000. Citadel Advisors LLC purchased a new position in Iterum Therapeutics in the fourth quarter valued at $38,000. Finally, Sanctuary Advisors LLC purchased a new position in Iterum Therapeutics in the fourth quarter valued at $35,000. Hedge funds and other institutional investors own 9.21% of the company’s stock.

Iterum Therapeutics Company Profile

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.